Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib versus platinum-based chemotherapy in first-line EGFR exon 20 insertion non-squamous NSCLC
2022-002006-24Phase 3Active
- Sponsor
- ArriVent BioPharma
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression-free survival. Started Dec 2022; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2022-002006-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002006-24.